| Literature DB >> 22985301 |
Li Jin Pu1, Ying Shen, Lin Lu, Rui Yan Zhang, Qi Zhang, Wei Feng Shen.
Abstract
BACKGROUND: Non-enzymatic glycation increases hemoglobin-oxygen affinity and reduces oxygen delivery to tissues by altering the structure and function of hemoglobin.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22985301 PMCID: PMC3489581 DOI: 10.1186/1475-2840-11-110
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Baseline characteristiecs and biochemical assessments
| Male gender (%) | 104(70.7) | 78(68.4) | 0.685 |
| Age (yrs) | 67±6 | 69±7 | 0.01 |
| Chronic obstructive pulmonary disease (%) | 98(66.7) | 81(71.1) | 0.449 |
| Cardiogenic pulmonary edema (%) | 13(8.8) | 17(14.9) | 0.127 |
| Pneumonia (%) | 40(27.2) | 46(40.4) | 0.025 |
| Hypertension (%) | 49(33.3) | 40(35.1) | 0.243 |
| Systolic blood pressure (mmHg) | 131±9 | 132±9 | 0.374` |
| Diastolic blood pressure (mmHg) | 75±8 | 76±8 | 0.317 |
| Red blood cell (x1012/L) | 4.75±0.73 | 4.91±0.77 | 0.088 |
| Hemoglobin (g/L) | 132±12 | 134±13 | 0.199 |
| Body temperature (°C) | 37.3±0.1 | 37.4 ± 0.1 | <0.001 |
| Total cholesterol (mmo1/L) | 4.06±0.91 | 4.17±0.95 | 0.343 |
| HDL-cholesterol (mmo1/L) | 1.19±0.26 | 1.17±0.27 | 0.545 |
| LDL-cholesterol (mmo1/L) | 2.43±0.62 | 2.41±0.68 | 0.805 |
| Triglycerides (mmo1/L) | 1.72±0.75 | 1.91± 0.78 | 0.047 |
| Fasting Glucose (mmo1/L) | 5.9±1.8 | 9.4±2.1 | <0.001 |
| 2-h postprandial glucose (mmo1/L) | 9.2±4.1 | 13.9± 4.5 | <0.001 |
| HbA1c (%) | 5.6±1.2 | 9.2±2.1 | <0.001 |
| Blood urea nitrogen (mmo1/L) | 5.42±2.35 | 6.03±2.51 | 0.045 |
| Creatinine (μmo1/L) | 87±16 | 91±18 | 0.59 |
| Medical treatments | | | |
| ACEI or ARB (%) | 46(31.3) | 37(32.5) | 0.841 |
| Calcium channel blocker (%) | 14(9.5) | 12(10.5) | 0.789 |
| Statins* (%) | 121(82.3) | 97(85.1) | 0.549 |
| Metformin (%) | 52(35.4) | 45(39.5) | 0.497 |
| Sulphonylureas (%) | 56(38.1) | 37(32.5) | 0.345 |
| Alpha-glucosidase (%) | 54(36.7) | 46(40.3) | 0.551 |
| PPAR-gamma agonist (%) | 23(15.6) | 15(13.2) | 0.572 |
Data are mean ± SD or number (%).
Abbreviation: HbA1c, Glycosylated hemoglobin A1c; HDL, High-density lipoprotein.
LDL, low-density lipoprotein; ACEI, andgiotensin-converting enzyme inhibitor.
ARB, angiotensin II receptor blocker.
*Statins: mainly simvastatin, pravastatin and atorvastatin.
Arterial blood gas analysis, 2,3-DPG level and SpObetween two groups
| 2, 3-DPG(μmo1/gHb) | 13.9±1.7 | 14.2±1.7 | 0.09 |
| pH | 7.37±0.05 | 7.39±0.05 | 0.01 |
| PCO2 (Kpa) | 5.48±0.73 | 5.53±0.65 | 0.565 |
| Carboxyhemoglobin (%) | 1.08±0.81 | 1.09±0.78 | 0.92 |
| PO2 (Kpa) | 10.0±1.9 | 10.0±2.2 | 0.843 |
| SaO2 (%) | 95.1±2.8 | 96.2±2.9 | 0.002 |
| SpO2 (%) | 95.3±2.8 | 98.0±2.6 | 0.001 |
Data are mean ± SD.
Abbreviation: 2,3-DPG, 2, 3-diphosphosglycerate.
PCO2, partial pressure of carbon dioxide.
PO2, partial pressure of oxygen; SaO2, arterial oxygen saturation.
SpO2, pulse oximeter oxygen saturation.
Figure 1Correlation of the difference between SpOand SaOwith blood HbA1c levels in patients with poor glycemic control.
Figure 2Arterial oxyhemoglobin sigmoid curves (PO, partial pressure of oxygen; SaOarterial oxygen saturation).
Figure 3Bland-Altman plots for bias and limits of agreement in patients with poor glycemic control.